

Yasuyuki Kimura

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6189387/publications.pdf>

Version: 2024-02-01

89
papers

1,861
citations

257429

24
h-index

315719

38
g-index

96
all docs

96
docs citations

96
times ranked

2520
citing authors

#	ARTICLE	IF	CITATIONS
1	Pharmacokinetic and pharmacodynamic assessment of histamine H3 receptor occupancy by enersant: a human PET study with a novel H3 binding ligand, [11C]TASP457. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 1127-1135.	6.4	3
2	Patterns of Distribution of 18F-THK5351 Positron Emission Tomography in Alzheimer's Disease Continuum. <i>Journal of Alzheimer's Disease</i> , 2022, 85, 223-234.	2.6	4
3	Brain 5-HT2A receptor binding and its neural network related to behavioral inhibition system. <i>Brain Imaging and Behavior</i> , 2022, 16, 1337-1348.	2.1	4
4	First-in-human in vivo imaging and quantification of monoacylglycerol lipase in the brain: a PET study with 18F-T-401. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 3150-3161.	6.4	3
5	[11C]NCGG401, a novel PET ligand for imaging of colony stimulating factor 1 receptors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2022, 65, 128704.	2.2	9
6	PET-based classification of corticobasal syndrome. <i>Parkinsonism and Related Disorders</i> , 2022, 98, 92-98.	2.2	5
7	Excess tau PET ligand retention in elderly patients with major depressive disorder. <i>Molecular Psychiatry</i> , 2021, 26, 5856-5863.	7.9	15
8	Differential associations of dopamine synthesis capacity with the dopamine transporter and D2 receptor availability as assessed by PET in the living human brain. <i>NeuroImage</i> , 2021, 226, 117543.	4.2	9
9	High-Contrast In Vivo Imaging of Tau Pathologies in Alzheimer's and Non-Alzheimer's Disease Tauopathies. <i>Neuron</i> , 2021, 109, 42-58.e8.	8.1	157
10	Biodistribution and radiation dosimetry of the positron emission tomography probe for AMPA receptor, [11C]K-2, in healthy human subjects. <i>Scientific Reports</i> , 2021, 11, 1598.	3.3	8
11	PET imaging of colony-stimulating factor 1 receptor: A head-to-head comparison of a novel radioligand, ¹¹ C-GW2580, and ¹¹ C-CPPC, in mouse models of acute and chronic neuroinflammation and a rhesus monkey. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2021, 41, 2410-2422.	4.3	36
12	Relationship between regional gray matter volumes and dopamine D2 receptor and transporter in living human brains. <i>Human Brain Mapping</i> , 2021, 42, 4048-4058.	3.6	3
13	Dynamic alterations in the central glutamatergic status following food and glucose intake: in vivo multimodal assessments in humans and animal models. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2021, 41, 2928-2943.	4.3	4
14	Evaluation of PiB visual interpretation with CSF A β 2 and longitudinal SUVR in J-ADNI study. <i>Annals of Nuclear Medicine</i> , 2020, 34, 108-118.	2.2	7
15	Brain pharmacokinetics and biodistribution of 11C-labeled isoproterenol in rodents. <i>Nuclear Medicine and Biology</i> , 2020, 86-87, 52-58.	0.6	5
16	PET/CT for Neuroinflammation. , 2020, , 217-228.		1
17	SPECT and PET of the Brain. , 2020, , 211-231.		0
18	Synthesis of (R,S)-isoproterenol, an inhibitor of tau aggregation, as an 11C-labeled PET tracer via reductive alkylation of (R,S)-norepinephrine with [2-11C]acetone. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2019, 29, 2107-2111.	2.2	3

#	ARTICLE	IF	CITATIONS
19	Correction of head movement by frame-to-frame image realignment for receptor imaging in positron emission tomography studies with [¹¹ C]raclopride and [¹¹ C]FLB 457. <i>Annals of Nuclear Medicine</i> , 2019, 33, 916-929.	2.2	5
20	PET-detectable tau pathology correlates with long-term neuropsychiatric outcomes in patients with traumatic brain injury. <i>Brain</i> , 2019, 142, 3265-3279.	7.6	54
21	First prototyping of a dedicated PET system with the hemisphere detector arrangement. <i>Physics in Medicine and Biology</i> , 2019, 64, 065004.	3.0	31
22	In vivo binding of a tau imaging probe, [¹¹ C]PBB3, in patients with progressive supranuclear palsy. <i>Movement Disorders</i> , 2019, 34, 744-754.	3.9	36
23	Tau imaging detects distinctive distribution of tau pathology in ALS/PDC on the Kii Peninsula. <i>Neurology</i> , 2019, 92, e136-e147.	1.1	19
24	[¹¹ C](R)-Rolipram positron emission tomography detects DISC1 inhibition of phosphodiesterase type 4 in live Disc1 locus-impaired mice. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2019, 39, 1306-1313.	4.3	3
25	Histamine H3 receptor density is negatively correlated with neural activity related to working memory in humans. <i>EJNMMI Research</i> , 2018, 8, 48.	2.5	6
26	Neuromolecular basis of faded perception associated with unreality experience. <i>Scientific Reports</i> , 2018, 8, 8062.	3.3	2
27	Tau-induced focal neurotoxicity and network disruption related to apathy in Alzheimer's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2018, 89, 1208-1214.	1.9	30
28	Association between A β ² and tau accumulations and their influence on clinical features in aging and Alzheimer's disease spectrum brains: A [¹¹ C]PBB3 PET study. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2017, 6, 11-20.	2.4	66
29	729. Delayed-Onset Psychosis following TBI is Associated with Tau Depositions in the Neocortex but Not with β -Amyloid Depositions: A Pet Study with [¹¹ C]PBB3 and [¹¹ C]PiB. <i>Biological Psychiatry</i> , 2017, 81, S295-S296.	1.3	1
30	PET Quantification of the Norepinephrine Transporter in Human Brain with [¹⁸ F]-FMeNER-D ₂ . <i>Journal of Nuclear Medicine</i> , 2017, 58, 1140-1145.	5.0	18
31	950. Increased Pet-Detectable Tau Pathologies in Late-Life Depression with Psychosis. <i>Biological Psychiatry</i> , 2017, 81, S384-S385.	1.3	0
32	Affinity States of Striatal Dopamine D2 Receptors in Antipsychotic-Free Patients with Schizophrenia. <i>International Journal of Neuropsychopharmacology</i> , 2017, 20, 928-935.	2.1	20
33	[¹⁸ F]-FMeNER-D ₂ : FIRST HUMAN PET STUDY WITH [¹⁸ F]-FMeNER-D ₂ AND [¹⁸ F]-FMeNER-D ₂ . <i>Alzheimer's and Dementia</i> , 2017, 13, P146.	0.8	10
34	Visual evaluation of kinetic characteristics of PET probe for neuroreceptors using a two-phase graphic plot analysis. <i>Annals of Nuclear Medicine</i> , 2017, 31, 273-282.	2.2	2
35	Normative data of dopaminergic neurotransmission functions in substantia nigra measured with MRI and PET: Neuromelanin, dopamine synthesis, dopamine transporters, and dopamine D2 receptors. <i>NeuroImage</i> , 2017, 158, 12-17.	4.2	19
36	Measurement of psychological state changes at low dopamine transporter occupancy following a clinical dose of mazindol. <i>Psychopharmacology</i> , 2017, 234, 323-328.	3.1	7

#	ARTICLE	IF	CITATIONS
37	Norepinephrine Transporter in Major Depressive Disorder: A PET Study. American Journal of Psychiatry, 2017, 174, 36-41.	7.2	38
38	Comparison of two PET radioligands, [11C]FPEB and [11C]SP203, for quantification of metabotropic glutamate receptor 5 in human brain. Journal of Cerebral Blood Flow and Metabolism, 2017, 37, 2458-2470.	4.3	21
39	[P3 ³⁷⁸]: FIRST HUMAN PET STUDY WITH ¹⁸ F-AM-PBB3 AND ¹⁸ F-PM-PBB3. Alzheimer's and Dementia, 2017, 13, P1104.	0.8	4
40	Occupancy of Norepinephrine Transporter by Duloxetine in Human Brains Measured by Positron Emission Tomography with (S,S)-[18F]FMeNER-D2. International Journal of Neuropsychopharmacology, 2017, 20, 957-962.	2.1	35
41	A human PET study of [11C]HMS011, a potential radioligand for AMPA receptors. EJNMMI Research, 2017, 7, 63.	2.5	17
42	Anatomical relationships between serotonin 5-HT2A and dopamine D2 receptors in living human brain. PLoS ONE, 2017, 12, e0189318.	2.5	8
43	PET imaging-guided chemogenetic silencing reveals a critical role of primate rostromedial caudate in reward evaluation. Nature Communications, 2016, 7, 13605.	12.8	96
44	Development of TASP0410457 (TASP457), a novel dihydroquinolinone derivative as a PET radioligand for central histamine H3 receptors. EJNMMI Research, 2016, 6, 11.	2.5	15
45	A new method to quantify tau pathologies with 11C-PBB3 PET using reference tissue voxels extracted from brain cortical gray matter. EJNMMI Research, 2016, 6, 24.	2.5	19
46	[11C]TASP457, a novel PET ligand for histamine H3 receptors in human brain. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 1653-1663.	6.4	13
47	PET Quantification in Molecular Brain Imaging Taking into Account the Contribution of the Radiometabolite Entering the Brain. , 2016, , 219-228.		0
48	Development of the helmet-chin PET prototype. , 2015, , .		14
49	PET Quantification of Tau Pathology in Human Brain with ¹¹ C-PBB3. Journal of Nuclear Medicine, 2015, 56, 1359-1365.	5.0	92
50	Evaluation of semi-quantitative method for quantification of dopamine transporter in human PET study with 18F-FE-PE2I. Annals of Nuclear Medicine, 2015, 29, 697-708.	2.2	9
51	Identification of a major radiometabolite of [11 C]PBB3. Nuclear Medicine and Biology, 2015, 42, 905-910.	0.6	37
52	Norepinephrine transporter occupancy by nortriptyline in patients with depression: a positron emission tomography study with (S,S)-[18F]FMeNER-D2. International Journal of Neuropsychopharmacology, 2014, 17, 553-560.	2.1	22
53	Reproducibility of PET measurement for presynaptic dopaminergic functions using L-[¹² -11C]DOPA and [18F]FE-PE2I in humans. Nuclear Medicine Communications, 2014, 35, 231-237.	1.1	14
54	Quantitative Analysis of Amyloid Deposition in Alzheimer Disease Using PET and the Radiotracer 11C-AZD2184. Journal of Nuclear Medicine, 2014, 55, 932-938.	5.0	17

#	ARTICLE	IF	CITATIONS
55	Biodistribution and radiation dosimetry in humans of [¹¹ C]FLB 457, a positron emission tomography ligand for the extrastriatal dopamine D2 receptor. <i>Nuclear Medicine and Biology</i> , 2014, 41, 102-105.	0.6	5
56	Test-retest reproducibility of dopamine D2/3 receptor binding in human brain measured by PET with [¹¹ C]MNPA and [¹¹ C]raclopride. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2013, 40, 574-579.	6.4	22
57	A MRI-based PET attenuation correction with λ -values measured by a fixed-position radiation source. , 2013, , .		0
58	Superiority illusion arises from resting-state brain networks modulated by dopamine. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 4363-4367.	7.1	30
59	Occupancy of serotonin and norepinephrine transporter by milnacipran in patients with major depressive disorder: a positron emission tomography study with [¹¹ C]DASB and (S,S)-[¹⁸ F]FMeNER-D2. <i>International Journal of Neuropsychopharmacology</i> , 2013, 16, 937-943.	2.1	36
60	Quantification of Dopamine Transporter in Human Brain Using PET with ¹⁸ F-FE-PE2I. <i>Journal of Nuclear Medicine</i> , 2012, 53, 1065-1073.	5.0	76
61	Quantification of metabotropic glutamate subtype 5 receptors in the brain by an equilibrium method using ¹⁸ F-SP203. <i>NeuroImage</i> , 2012, 59, 2124-2130.	4.2	13
62	Association between Striatal Subregions and Extrastriatal Regions in Dopamine D1 Receptor Expression: A Positron Emission Tomography Study. <i>PLoS ONE</i> , 2012, 7, e49775.	2.5	2
63	Striatal and extrastriatal dopamine D2 receptor occupancy by the partial agonist antipsychotic drug aripiprazole in the human brain: a positron emission tomography study with [¹¹ C]raclopride and [¹¹ C]FLB457. <i>Psychopharmacology</i> , 2012, 222, 165-172.	3.1	20
64	Synthesis and Evaluation of Radioligands for Imaging Brain Nociceptin/Orphanin FQ Peptide (NOP) Receptors with Positron Emission Tomography. <i>Journal of Medicinal Chemistry</i> , 2011, 54, 2687-2700.	6.4	62
65	Brain and Whole-Body Imaging in Rhesus Monkeys of ¹¹ C-NOP-1A, a Promising PET Radioligand for Nociceptin/Orphanin FQ Peptide Receptors. <i>Journal of Nuclear Medicine</i> , 2011, 52, 1638-1645.	5.0	50
66	Biodistribution and radiation dosimetry of a positron emission tomographic ligand, ¹⁸ F-SP203, to image metabotropic glutamate subtype 5 receptors in humans. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2010, 37, 1943-1949.	6.4	32
67	Biodistribution and Radiation Dosimetry in Humans of a New PET Ligand, ¹⁸ F-PBR06, to Image Translocator Protein (18 kDa). <i>Journal of Nuclear Medicine</i> , 2010, 51, 145-149.	5.0	42
68	Blood Pressure Lowering with Valsartan Is Associated with Maintenance of Cerebral Blood Flow and Cerebral Perfusion Reserve in Hypertensive Patients with Cerebral Small Vessel Disease. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2010, 19, 85-91.	1.6	18
69	Functional brain areas associated with manipulation of a prehensile tool: A PET study. <i>Human Brain Mapping</i> , 2009, 30, 2879-2889.	3.6	13
70	Statistical Parametric Analysis of Cerebral Blood Flow in Vascular Dementia with Small-Vessel Disease Using ^{99m} Tc-HMPAO SPECT. <i>Cerebrovascular Diseases</i> , 2008, 26, 556-562.	1.7	18
71	Cerebral Hemodynamics and Oxygen Metabolism in Patients with Moyamoya Syndrome Associated with Atherosclerotic Steno-Occlusive Arterial Lesions. <i>Cerebrovascular Diseases</i> , 2008, 26, 9-15.	1.7	19
72	Metabotropic Glutamate Subtype 5 Receptors Are Quantified in the Human Brain with a Novel Radioligand for PET. <i>Journal of Nuclear Medicine</i> , 2008, 49, 2042-2048.	5.0	57

#	ARTICLE	IF	CITATIONS
73	Chronic Middle Cerebral Artery Occlusion: A Hemodynamic and Metabolic Study with Positron-Emission Tomography. <i>American Journal of Neuroradiology</i> , 2008, 29, 1841-1846.	2.4	36
74	Hemodynamic Influences of Azelnidipine, a Novel Calcium Channel Blocker, on Cerebral Circulation in Hypertensive Patients with Ischemic White Matter Lesions. <i>Hypertension Research</i> , 2008, 31, 2147-2154.	2.7	11
75	Functional brain areas involved in the use of chopsticks: A PET study. <i>Neuroscience Research</i> , 2007, 58, S212.	1.9	0
76	Crossed cerebellar diaschisis: a positron emission tomography study withl-[methyl-11C]methionine and 2-deoxy-2-[18F]fluoro-d-glucose. <i>Annals of Nuclear Medicine</i> , 2007, 21, 109-113.	2.2	33
77	N-isopropyl-4-[123I]iodoamphetamine (123I-IMP) products: a difference in radiochemical purity, unmetabolized fraction, and octanol extraction fraction in arterial blood and regional brain uptake in rats. <i>Annals of Nuclear Medicine</i> , 2007, 21, 387-391.	2.2	7
78	Effect of linearization correction on statistical parametric mapping (SPM): A99mTc-HMPAO brain perfusion SPECT study in mild Alzheimerâ€™s disease. <i>Annals of Nuclear Medicine</i> , 2006, 20, 511-517.	2.2	11
79	Diastolic blood pressure influences cerebrovascular reactivity measured by means of123I-iodoamphetamine brain single photon emission computed tomography in medically treated patients with occlusive carotid or middle cerebral artery disease. <i>Annals of Nuclear Medicine</i> , 2006, 20, 209-215.	2.2	4
80	Hzf protein regulates dendritic localization and BDNF-induced translation of type 1 inositol 1,4,5-trisphosphate receptor mRNA. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2005, 102, 17190-17195.	7.1	24
81	Hemodynamic Influences of Losartan on the Brain in Hypertensive Patients. <i>Hypertension Research</i> , 2005, 28, 43-49.	2.7	30
82	Cerebrovascular collaterals and misery perfusion in patients with middle cerebral artery occlusion: A combined study with PET and angiography. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2005, 25, S342-S342.	4.3	0
83	Spectral analysis of99mTc-HMPAO for estimating cerebral blood flow: A comparison with H2 15O PET. <i>Annals of Nuclear Medicine</i> , 2004, 18, 243-249.	2.2	5
84	Cerebral hemodynamics and metabolism in adult moyamoya disease: Comparison of angiographic collateral circulation. <i>Annals of Nuclear Medicine</i> , 2004, 18, 115-121.	2.2	63
85	Cerebral and Cerebellar Activation in Power and Precision Grip Movements: An H215O Positron Emission Tomography Study. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2003, 23, 1378-1382.	4.3	15
86	Ipsilateral Hemiplegia in a Lateral Medullary Infarctâ€™s Opalskiâ€™s Syndrome. , 2003, 13, 83-84.		3
87	Pharmacokinetics of active vitamins D3, 1 alpha-hydroxyvitamin D3 and 1 alpha, 25-dihydroxyvitamin D3 in patients on chronic hemodialysis. <i>Clinical Nephrology</i> , 1991, 35, 72-7.	0.7	17
88	Age-related increase of monoamine oxidase B in amyloid-negative cognitively unimpaired elderly subjects. <i>Annals of Nuclear Medicine</i> , 0, , .	2.2	0
89	Measurement of Striatal Dopamine Release Induced by Neuropsychological Stimulation in Positron Emission Tomography With Dual Injections of [11C]Raclopride. <i>Frontiers in Psychiatry</i> , 0, 13, .	2.6	0